Nebulized Tranexamic Acid in Sinus Surgery

Key facts

Sponsor

Assiut University

Intervention

Tranexamic acid(drug)

Enrollment

90 target

Eligibility

18-65 years · All sexes

Timeline

2021 – 2026

Study locations (1)

• Assuit, Asyut, Assuit, Egypt

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Polyrrhinia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT06846385
  Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis
  Shanghai Mabgeek Biotech.Co.Ltd
• RECRUITINGPHASE3NCT06834360
  A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
  Sanofi
• RECRUITINGPHASE3NCT06615557
  Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
  VistaGen Therapeutics, Inc.
• RECRUITINGPHASE3NCT06338995
  A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
  Eli Lilly and Company
• ACTIVE NOT RECRUITINGPHASE2NCT06315426
  A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR).
  Genrix (Shanghai) Biopharmaceutical Co., Ltd.
• RECRUITINGPHASE2NCT06292923
  A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
  Tiziana Life Sciences LTD
• ACTIVE NOT RECRUITINGPHASE2NCT05891483
  Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps
  Guangdong Hengrui Pharmaceutical Co., Ltd

See all trials for Polyrrhinia →